- Home
- CAPR vs ORC Comparison
CAPR vs ORC Comparison
Compare CAPR & ORC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- ORC
- Stock Information
- Founded
- CAPR 2005
- ORC 2010
- Country
- CAPR United States
- ORC United States
- Employees
- CAPR N/A
- ORC N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- ORC Real Estate Investment Trusts
- Sector
- CAPR Health Care
- ORC Real Estate
- Exchange
- CAPR Nasdaq
- ORC Nasdaq
- Market Cap
- CAPR 622.9M
- ORC 623.6M
- IPO Year
- CAPR N/A
- ORC 2013
- Fundamental
- Price
- CAPR $12.79
- ORC $8.19
- Analyst Decision
- CAPR Strong Buy
- ORC Buy
- Analyst Count
- CAPR 7
- ORC 3
- Target Price
- CAPR $39.29
- ORC $9.50
- AVG Volume (30 Days)
- CAPR 1.5M
- ORC 3.5M
- Earning Date
- CAPR 03-19-2025
- ORC 04-24-2025
- Dividend Yield
- CAPR N/A
- ORC 17.60%
- EPS Growth
- CAPR N/A
- ORC N/A
- EPS
- CAPR N/A
- ORC 0.58
- Revenue
- CAPR $23,228,045.00
- ORC $54,406,000.00
- Revenue This Year
- CAPR N/A
- ORC N/A
- Revenue Next Year
- CAPR $74.85
- ORC $7.79
- P/E Ratio
- CAPR N/A
- ORC $14.22
- Revenue Growth
- CAPR 65.33
- ORC N/A
- 52 Week Low
- CAPR $3.52
- ORC $7.41
- 52 Week High
- CAPR $23.40
- ORC $9.08
- Technical
- Relative Strength Index (RSI)
- CAPR 42.76
- ORC 41.75
- Support Level
- CAPR $11.75
- ORC $8.02
- Resistance Level
- CAPR $16.17
- ORC $8.56
- Average True Range (ATR)
- CAPR 1.51
- ORC 0.20
- MACD
- CAPR -0.18
- ORC -0.08
- Stochastic Oscillator
- CAPR 22.96
- ORC 17.37
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc invests in residential mortgage-backed securities (RMBS) across the United States. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.